首页> 中文期刊> 《胃肠病学》 >糖皮质激素治疗重症酒精性肝炎的进展

糖皮质激素治疗重症酒精性肝炎的进展

         

摘要

重症酒精性肝炎(SAH)的特点为显著的肝脏组织炎症反应、血循环中高水平促炎因子、严重的凝血功能异常、血清胆红素增高以及迅速出现的肝功能衰竭,其治疗是临床争论和探索的焦点.在戒酒和营养支持的基础上,糖皮质激素是最常用于治疗SAH的药物之一,也是最具争议的药物.正确评估疾病的严重程度,合理、规范应用糖皮质激素以及标准化和个体化兼顾的处理方案是成功治疗SAH的关键.%Severe alcoholic hepatitis (SAH) is a nectotizing inflammatory lesion characterized by high circulating level of proinflammatory cytokines, severe coagulopathy, escalating serum bilirubin level and rapid deterioration of liver function. The management of SAH remains a challenge to the physicians. On the basis of abstinence from alcohol and nutritional support, glucocorticoids is the most frequently used and yet most debated drug for the treatment of SAH. Accurate clinical assessment of disease severity, rational use of glucocorticoids, standardized and individualized management strategies are of paramount importance for the treatment of SAH.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号